fair value 23c ready for 400% up, page-42

"NuSep is moving closer to completing its $15m funding for its Singapore based PrIME Biologics plasma fractionation business. This $15m fund raising assumes a valuation for
PrIME Biologics of $50m."

"As a result of this work the number of PrIME cartridges required to undertake a 250L batch of human plasma was reduced from 25 to 15 cartridges"

"In return for this A$15m of funding the investors will acquire a 30% interest in PrIME. A further 10% of PrIME will be issued to Luye in return for the Singapore
cGMP facility, leaving NuSep with a 60% ownership of PrIME. The A$50m valuation of PrIME is an agreed valuation which is further supported by an independent valuation of PrIME
commissioned by NuSep in May 2012. This independent valuation does not take into account the achievements noted above as they have all occurred post the valuation."